SCHEDULE 13D/A: KKR Reduces Stake in BridgeBio Pharma, Sells 6 Million Shares in Block Sale
Amendment to Schedule 13D
KKR Genetic Disorder L.P., a key investment entity of Kohlberg Kravis Roberts & Co. L.P., has significantly reduced its beneficial ownership in BridgeBio Pharma, Inc. by selling 6 million shares.
Summary
- KKR Genetic Disorder L.P. reported a beneficial ownership of 19,260,971 shares of BridgeBio Pharma, Inc. Common Stock as of March 5, 2025.
- This ownership represents approximately 10.1% of the outstanding Common Stock, based on 190,188,626 shares reported by BridgeBio Pharma, Inc. as of February 13, 2025.
- On March 5, 2025, KKR Genetic Disorder L.P. executed a block sale of 6,000,000 shares of Common Stock.
- The shares were sold at a price of $32.96 per share, pursuant to Rule 144 under the Securities Act of 1933.
- This filing, Amendment No. 5 to Schedule 13D, updates previous filings, with the initial Schedule 13D filed on July 10, 2019.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to a significant reduction in stake by a major institutional investor, which can imply a lack of increased confidence or a strategic exit from a portion of their investment, potentially impacting market perception.
Negatives
- A significant reduction in stake by a major institutional investor like KKR could be perceived negatively by the market, potentially signaling a change in their long-term outlook or a decision to reallocate capital.
Risks
- The sale of 6,000,000 shares by KKR Genetic Disorder L.P. could lead to increased selling pressure on BridgeBio Pharma's stock in the short term.
- A reduction in a major investor's stake might be interpreted by other investors as a decrease in confidence in the company's future prospects, potentially impacting investor sentiment.
Future Outlook
This Schedule 13D amendment primarily reports a past transaction and current ownership stake, and does not provide forward-looking statements or guidance from the issuer or the reporting persons regarding future business operations or financial performance.
Industry Context
This filing reflects a change in a significant institutional investor's position within the biotechnology and pharmaceutical sector. KKR, a major private equity firm, is adjusting its stake in BridgeBio Pharma, a company focused on genetic diseases. Such large block sales by institutional investors can influence market perception within the specialized biopharma industry, where investor confidence in long-term drug development pipelines is crucial.
Stakeholder Impact
- Shareholders: The reduction in KKR's stake could lead to concerns among other shareholders about the company's future prospects or valuation, potentially impacting the stock price.
- Investors: Other institutional and retail investors may re-evaluate their positions in BridgeBio Pharma based on this significant sale by a prominent investment firm.
Key Dates
| Date | Description |
|---|---|
| 2019-07-10 | Initial Schedule 13D filing date. |
| 2020-06-01 | Amendment No. 1 to Schedule 13D filed. |
| 2020-10-06 | Amendment No. 2 to Schedule 13D filed. |
| 2021-02-17 | Amendment No. 3 to Schedule 13D filed. |
| 2024-09-17 | Amendment No. 4 to Schedule 13D filed and date of Joint Filing Agreement. |
| 2025-02-13 | Date as of which BridgeBio Pharma, Inc. reported 190,188,626 shares of Common Stock outstanding in its Form 10-K. |
| 2025-02-20 | Date BridgeBio Pharma, Inc. filed its Form 10-K with the SEC. |
| 2025-03-05 | Date of the block sale of 6,000,000 shares by KKR Genetic Disorder L.P. |
| 2025-03-07 | Date of signing for Amendment No. 5 to Schedule 13D. |
Keywords
Schedule 13D, BridgeBio Pharma, KKR, Beneficial Ownership, Block Sale, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.